JP6899975B2 - Ｍｃｌ−１阻害剤 - Google Patents

Ｍｃｌ−１阻害剤 Download PDF

Info

Publication number
JP6899975B2
JP6899975B2 JP2020564228A JP2020564228A JP6899975B2 JP 6899975 B2 JP6899975 B2 JP 6899975B2 JP 2020564228 A JP2020564228 A JP 2020564228A JP 2020564228 A JP2020564228 A JP 2020564228A JP 6899975 B2 JP6899975 B2 JP 6899975B2
Authority
JP
Japan
Prior art keywords
formula
alkyl
cycloalkyl
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020564228A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021515030A (ja
Inventor
ハン チュー，
ハン チュー，
フアン エー． ゲレロ，
フアン エー． ゲレロ，
アンナ イー． ハートレー，
アンナ イー． ハートレー，
タエ エイチ． ウォン，
タエ エイチ． ウォン，
ラン ジアン，
ラン ジアン，
ダリル カトウ，
ダリル カトウ，
徹也 小林
徹也 小林
ジョン イー． ノックス，
ジョン イー． ノックス，
スコット イー． レザーウィズ，
スコット イー． レザーウィズ，
シャオフェン リー，
シャオフェン リー，
デイビッド ダブリュー． リン，
デイビッド ダブリュー． リン，
ジョナサン ダブリュー． メドレー，
ジョナサン ダブリュー． メドレー，
マイケル エル． ミッチェル，
マイケル エル． ミッチェル，
デヴァン ナドゥサンビ，
デヴァン ナドゥサンビ，
ザカリー ニュービー，
ザカリー ニュービー，
ニール エイチ． スクワイアーズ，
ニール エイチ． スクワイアーズ，
ヴィッキー エイチ． ツイ，
ヴィッキー エイチ． ツイ，
チャンドラセカール ベンカタラマニ，
チャンドラセカール ベンカタラマニ，
ウィリアム ジェイ． ワトキンス，
ウィリアム ジェイ． ワトキンス，
ホン ヤン，
ホン ヤン，
Original Assignee
ギリアード サイエンシーズ， インコーポレイテッド
ギリアード サイエンシーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ギリアード サイエンシーズ， インコーポレイテッド, ギリアード サイエンシーズ， インコーポレイテッド filed Critical ギリアード サイエンシーズ， インコーポレイテッド
Priority to JP2021037000A priority Critical patent/JP7240431B2/ja
Publication of JP2021515030A publication Critical patent/JP2021515030A/ja
Application granted granted Critical
Publication of JP6899975B2 publication Critical patent/JP6899975B2/ja
Priority to JP2023032872A priority patent/JP2023060145A/ja
Priority to JP2025080314A priority patent/JP7792036B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D267/20—[b, f]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • C07C381/10—Compounds containing sulfur atoms doubly-bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
JP2020564228A 2018-05-14 2019-05-13 Ｍｃｌ−１阻害剤 Active JP6899975B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021037000A JP7240431B2 (ja) 2018-05-14 2021-03-09 Ｍｃｌ－１阻害剤
JP2023032872A JP2023060145A (ja) 2018-05-14 2023-03-03 Ｍｃｌ－１阻害剤
JP2025080314A JP7792036B2 (ja) 2018-05-14 2025-05-13 Ｍｃｌ－１阻害剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862671306P 2018-05-14 2018-05-14
US62/671,306 2018-05-14
US201862749918P 2018-10-24 2018-10-24
US62/749,918 2018-10-24
PCT/US2019/032053 WO2019222112A1 (en) 2018-05-14 2019-05-13 Mcl-1 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021037000A Division JP7240431B2 (ja) 2018-05-14 2021-03-09 Ｍｃｌ－１阻害剤

Publications (2)

Publication Number Publication Date
JP2021515030A JP2021515030A (ja) 2021-06-17
JP6899975B2 true JP6899975B2 (ja) 2021-07-07

Family

ID=66770559

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020564228A Active JP6899975B2 (ja) 2018-05-14 2019-05-13 Ｍｃｌ−１阻害剤
JP2021037000A Active JP7240431B2 (ja) 2018-05-14 2021-03-09 Ｍｃｌ－１阻害剤
JP2023032872A Pending JP2023060145A (ja) 2018-05-14 2023-03-03 Ｍｃｌ－１阻害剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021037000A Active JP7240431B2 (ja) 2018-05-14 2021-03-09 Ｍｃｌ－１阻害剤
JP2023032872A Pending JP2023060145A (ja) 2018-05-14 2023-03-03 Ｍｃｌ－１阻害剤

Country Status (30)

Country Link
US (5) US10703733B2 (enExample)
EP (2) EP4029868A1 (enExample)
JP (3) JP6899975B2 (enExample)
KR (4) KR102732008B1 (enExample)
CN (2) CN112118845B (enExample)
AU (3) AU2019269391B2 (enExample)
BR (1) BR112020021648A2 (enExample)
CA (1) CA3099152C (enExample)
CL (1) CL2020002919A1 (enExample)
CO (1) CO2020014009A2 (enExample)
CR (1) CR20200544A (enExample)
CY (1) CY1125065T1 (enExample)
DK (1) DK3793565T3 (enExample)
ES (1) ES2907923T3 (enExample)
HR (1) HRP20220215T1 (enExample)
HU (1) HUE057852T2 (enExample)
IL (2) IL291430B2 (enExample)
LT (1) LT3793565T (enExample)
MX (1) MX2020012137A (enExample)
MY (1) MY198871A (enExample)
PE (1) PE20210004A1 (enExample)
PH (1) PH12020551881A1 (enExample)
PL (1) PL3793565T3 (enExample)
PT (1) PT3793565T (enExample)
SG (1) SG11202010964VA (enExample)
SI (1) SI3793565T1 (enExample)
TW (4) TWI813957B (enExample)
UA (1) UA125163C2 (enExample)
WO (1) WO2019222112A1 (enExample)
ZA (1) ZA202007007B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102732008B1 (ko) 2018-05-14 2024-11-20 길리애드 사이언시즈, 인코포레이티드 Mcl-1 억제제
EP3643711A1 (en) 2018-10-24 2020-04-29 Bayer Animal Health GmbH New anthelmintic compounds
ES2987630T3 (es) 2019-07-09 2024-11-15 Janssen Pharmaceutica Nv Derivados de espirociclos macrocíclicos como inhibidores de MCL-1
US11795223B2 (en) 2019-10-18 2023-10-24 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
MX2022005123A (es) 2019-10-31 2022-05-30 Forty Seven Inc Tratamiento basado en anti-cd47 y anti-cd20 para cancer hematologico.
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
US11325891B2 (en) 2019-11-26 2022-05-10 Gilead Sciences, Inc. Processes and intermediates for preparing MCL1 inhibitors
MX2022007930A (es) 2019-12-24 2022-08-08 Carna Biosciences Inc Compuestos moduladores de diacilglicerol quinasa.
US20230212191A1 (en) * 2020-04-16 2023-07-06 Prelude Therapeutics, Incorporated Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein
US20230219906A1 (en) 2020-06-10 2023-07-13 Janssen Pharmaceutica Nv Macrocyclic-2-amino-3-fluoro-but-3-enamides as inhibitors of mcl-1
CN116457334A (zh) * 2020-11-19 2023-07-18 吉利德科学公司 用于制备大环mcl1抑制剂的方法和中间体
ES3026771T3 (en) 2020-12-17 2025-06-12 Janssen Pharmaceutica Nv Macrocyclic branched 3-fluoro-but-3-enamides as inhibitors of mcl-1
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
AU2022267722A1 (en) 2021-04-26 2023-12-14 Janssen Pharmaceutica Nv Macrocyclic 2-allyltetrahydrofurans as inhibitors of mcl-1
US20220389394A1 (en) 2021-05-18 2022-12-08 Gilead Sciences, Inc. METHODS OF USING FLT3L-Fc FUSION PROTEINS
WO2022261310A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-body drug conjugates
CN117651554A (zh) * 2021-06-11 2024-03-05 吉利德科学公司 Mcl-1抑制剂与抗癌剂的组合
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
JP7686086B2 (ja) 2021-06-23 2025-05-30 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリエルコール（ｄｉａｃｙｌｇｌｙｅｒｃｏｌ）キナーゼ調節化合物
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
MX2024005928A (es) 2021-11-16 2024-06-04 Janssen Pharmaceutica Nv 2-amino-but-3-enamidas macrociclicas como inhibidores de mcl-1.
JP2025509662A (ja) 2022-03-24 2025-04-11 ギリアード サイエンシーズ， インコーポレイテッド Ｔｒｏｐ－２発現がんを治療するための併用療法
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
US12162896B2 (en) * 2022-05-04 2024-12-10 Gilead Sciences, Inc. Salts and polymorphs of certain MCL-1 inhibitors
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
WO2005014599A1 (en) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
WO2005113556A1 (en) 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
US20090142345A1 (en) 2005-03-15 2009-06-04 Takeda Pharmaceutical Company Limited Prophylactic/therapeutic agent for cancer
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
KR101411165B1 (ko) 2005-07-01 2014-06-25 메다렉스, 엘.엘.시. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
HUE029188T2 (en) 2007-03-12 2017-03-28 Ym Biosciences Australia Pty Phenylamino-pyrimidine compounds and their use
CN110372795A (zh) 2007-08-02 2019-10-25 吉利德生物制剂公司 Lox和loxl2抑制剂及其应用
PL2310509T3 (pl) 2008-07-21 2015-08-31 Apogenix Ag Jednołańcuchowe cząsteczki TNFSF
US8652843B2 (en) 2008-08-12 2014-02-18 Oncomed Pharmaceuticals, Inc. DDR1-binding agents and methods of use thereof
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
TWI625121B (zh) 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
RU2015108348A (ru) 2010-02-04 2015-07-20 Джилид Байолоджикс, Инк. Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
AU2011293125B2 (en) 2010-08-27 2015-02-05 Gilead Sciences, Inc. Antibodies to matrix metalloproteinase 9
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
TWI567061B (zh) 2011-07-01 2017-01-21 吉李德科學股份有限公司 用於治療成癮之化合物
US9550835B2 (en) 2011-08-23 2017-01-24 Chugai Seiyaku Kabushiki Kaisha Anti-DDR1 antibody having anti-tumor activity
GB201115529D0 (en) 2011-09-08 2011-10-26 Imp Innovations Ltd Antibodies, uses and methods
CA2850763A1 (en) 2011-10-04 2013-04-11 Gilead Calistoga Llc Novel quinoxaline inhibitors of pi3k
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
WO2013116562A1 (en) 2012-02-03 2013-08-08 Gilead Calistoga Llc Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
UY35044A (es) 2012-09-24 2014-04-30 Gilead Sciences Inc ANTICUERPOS ANTI-dDr1
US9029384B2 (en) 2012-12-21 2015-05-12 Gilead Calistoga, LLC. Phosphatidylinositol 3-kinase inhibitors
AU2013364068B2 (en) 2012-12-21 2016-10-20 Gilead Calistoga Llc Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
TWI644909B (zh) 2013-06-14 2018-12-21 基利科學股份有限公司 磷脂酸肌醇３－激酶抑制劑
MX2016001304A (es) 2013-07-30 2016-04-07 Gilead Connecticut Inc Polimorfo de inhibidores de syk.
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
CA2943815C (en) * 2014-03-27 2023-04-04 Vanderbilt University Substituted indole mcl-1 inhibitors
SG11201608393TA (en) 2014-04-10 2016-11-29 Seattle Children S Hospital Dba Seattle Children S Res Inst Transgene genetic tags and methods of use
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
JO3474B1 (ar) * 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
CN106715419A (zh) 2014-09-26 2017-05-24 吉利德科学公司 用作tank‑结合激酶抑制剂化合物的氨基三嗪衍生物
EP3227323B1 (en) 2014-12-03 2020-08-05 Juno Therapeutics, Inc. Methods and compositions for adoptive cell therapy
CA2966234A1 (en) 2014-12-15 2016-06-23 Bellicum Pharmaceuticals, Inc. Methods for controlled elimination of therapeutic cells
WO2016186967A1 (en) 2015-05-15 2016-11-24 Gilead Sciences, Inc. Benzimidazole and imadazopyridine carboximidamide compounds having activity as inhibitors of indoleamine 2,3-dioxygenase
WO2016196388A1 (en) 2015-05-29 2016-12-08 Juno Therapeutics, Inc. Composition and methods for regulating inhibitory interactions in genetically engineered cells
MX2018003353A (es) 2015-09-17 2018-09-17 Novartis Ag Terapias con celulas cart con una eficacia mejorada.
US11306107B2 (en) 2016-02-25 2022-04-19 Amgen Inc. Compounds that inhibit MCL-1 protein
JP6453507B2 (ja) 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Ｍｃｌ−１タンパク質を阻害する化合物
EP3668878B1 (en) 2017-08-18 2025-05-21 Amgen Inc. Compounds that inhibit mcl-1 protein
US11279712B2 (en) 2017-08-29 2022-03-22 Amgen Inc. Macrocyclic compounds that inhibit MCL-1 protein
CA3079081A1 (en) 2017-10-19 2019-04-25 Michael D. Bartberger Benzimidazole derivatives and their uses
MA54985A (fr) 2018-03-05 2021-12-29 Amgen Inc Pharmacophores d'acide alpha-hydroxy phénylacétique ou antagonistes de la protéine bio-isostère mcl-1
EP3794009A1 (en) 2018-05-14 2021-03-24 Reata Pharmaceuticals, Inc. Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway
KR102732008B1 (ko) 2018-05-14 2024-11-20 길리애드 사이언시즈, 인코포레이티드 Mcl-1 억제제
SG11202011228TA (en) 2018-05-15 2020-12-30 Lundbeck La Jolla Research Center Inc Magl inhibitors
SG11202100158WA (en) 2018-07-24 2021-02-25 Epizyme Inc Pyridin-2-one compounds useful as smarca2 antagonists
JP2022506973A (ja) 2018-11-09 2022-01-17 プレリュード セラピューティクス，インコーポレイティド 骨髄性細胞白血病－１（ｍｃｌ－１）タンパク質の阻害剤としてのスピロ－スルホンアミド誘導体
WO2020147802A1 (en) 2019-01-18 2020-07-23 Ascentage Pharma (Suzhou) Co., Ltd. Macrocyclic spiroethers as mcl-1 inhibitors
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
US11325891B2 (en) 2019-11-26 2022-05-10 Gilead Sciences, Inc. Processes and intermediates for preparing MCL1 inhibitors
JP2021161114A (ja) 2020-03-31 2021-10-11 アムジエン・インコーポレーテツド Ｍｃｌ−１化合物のメチル化
CA3181214A1 (en) 2020-05-06 2021-11-11 Amgen Inc. Synthesis of vinylic protected alcohol intermediates
TWI827924B (zh) 2020-05-06 2024-01-01 美商安進公司 大環Mcl-1抑制劑中間體的閉環合成
US20230219906A1 (en) 2020-06-10 2023-07-13 Janssen Pharmaceutica Nv Macrocyclic-2-amino-3-fluoro-but-3-enamides as inhibitors of mcl-1
EP4178677A1 (en) 2020-07-08 2023-05-17 JANSSEN Pharmaceutica NV Macrocyclic ether containing indole derivatives as inhibitors of mcl-1
CN116457334A (zh) 2020-11-19 2023-07-18 吉利德科学公司 用于制备大环mcl1抑制剂的方法和中间体

Also Published As

Publication number Publication date
CY1125065T1 (el) 2023-06-09
AU2019269391B2 (en) 2021-02-25
JP2025109849A (ja) 2025-07-25
JP2021515030A (ja) 2021-06-17
KR102666717B1 (ko) 2024-05-20
US20230312490A1 (en) 2023-10-05
KR20240074001A (ko) 2024-05-27
CN112118845A (zh) 2020-12-22
CN112118845B (zh) 2023-06-13
ES2907923T3 (es) 2022-04-27
JP7240431B2 (ja) 2023-03-15
IL291430B2 (en) 2024-04-01
WO2019222112A8 (en) 2020-11-12
PL3793565T3 (pl) 2022-05-02
CN117304130A (zh) 2023-12-29
TWI844454B (zh) 2024-06-01
KR20210006981A (ko) 2021-01-19
ZA202007007B (en) 2023-11-29
BR112020021648A2 (pt) 2021-01-26
US12162844B2 (en) 2024-12-10
US10988451B2 (en) 2021-04-27
TW202506687A (zh) 2025-02-16
EP4029868A1 (en) 2022-07-20
CA3099152A1 (en) 2019-11-21
IL278336B (en) 2022-04-01
US11643400B2 (en) 2023-05-09
KR20230107889A (ko) 2023-07-18
KR20240165483A (ko) 2024-11-22
US20250154116A1 (en) 2025-05-15
KR102551319B1 (ko) 2023-07-05
CO2020014009A2 (es) 2020-11-30
PT3793565T (pt) 2022-04-13
IL291430A (en) 2022-05-01
JP2023060145A (ja) 2023-04-27
AU2019269391A1 (en) 2020-11-19
MX2020012137A (es) 2021-01-29
US10703733B2 (en) 2020-07-07
US20200331870A1 (en) 2020-10-22
TWI813957B (zh) 2023-09-01
NZ769257A (en) 2024-05-31
CR20200544A (es) 2021-02-11
CL2020002919A1 (es) 2021-04-16
US20190352271A1 (en) 2019-11-21
AU2023270332B2 (en) 2025-10-02
TW202010740A (zh) 2020-03-16
MY198871A (en) 2023-10-02
TW202417457A (zh) 2024-05-01
HUE057852T2 (hu) 2022-06-28
IL291430B1 (en) 2023-12-01
JP2021098728A (ja) 2021-07-01
AU2021203373B2 (en) 2023-09-14
HRP20220215T1 (hr) 2022-04-29
SI3793565T1 (sl) 2022-04-29
AU2021203373A1 (en) 2021-06-24
AU2023270332A1 (en) 2023-12-14
EP3793565B1 (en) 2022-01-05
LT3793565T (lt) 2022-02-25
UA125163C2 (uk) 2022-01-19
TW202122403A (zh) 2021-06-16
WO2019222112A1 (en) 2019-11-21
PE20210004A1 (es) 2021-01-05
US20220340535A1 (en) 2022-10-27
EP3793565A1 (en) 2021-03-24
TWI719478B (zh) 2021-02-21
DK3793565T3 (en) 2022-03-07
PH12020551881A1 (en) 2021-05-31
KR102732008B1 (ko) 2024-11-20
SG11202010964VA (en) 2020-12-30
CA3099152C (en) 2023-10-24

Similar Documents

Publication Publication Date Title
JP6899975B2 (ja) Ｍｃｌ−１阻害剤
JP7792036B2 (ja) Ｍｃｌ－１阻害剤
HK40078700A (en) Mcl-1 inhibitors
HK40038496B (en) Mcl-1 inhibitors
HK40048157A (en) Mcl-1 inhibitors
HK40048157B (en) Mcl-1 inhibitors
EA043742B1 (ru) Ингибиторы mcl-1
HK40038496A (en) Mcl-1 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210112

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210309

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210112

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210309

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20210412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210528

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210611

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210615

R150 Certificate of patent or registration of utility model

Ref document number: 6899975

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250